Polymorphisms in the MDM2 gene and risk of malignant bone tumors: A meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 779-784

  Tang, Jianfei ^a   Shen, Longxiang ^a   Song, Sa ^a   An, Zhiquan ^a   Zhang, Changqing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bone tumors; MDM2; Meta analysis; Polymorphism

Indexed keywords

PROTEIN MDM2;

ALLELE; ARTICLE; BONE TUMOR; CANCER RISK; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MDM2 GENE; MEDICAL LITERATURE; ONCOGENE; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ALLELES; BONE NEOPLASMS; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK;

EID: 84894468803     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1106-3     Document Type: Article

References (25)

1. Hameed M, Dorfman H. Primary malignant bone tumors-recent developments. Semin Diagn Pathol. 2011;28:86-101.
2. Eyre R, Feltbower RG, Mubwandarikwa E, Eden TO, McNally RJ. Epidemiology of bone tumours in children and young adults. Pediatr Blood Cancer. 2009;53:941-52.
3. Rajiah P, Ilaslan H, Sundaram M. Imaging of primary malignant bone tumors (nonhematological). Radiol Clin North Am. 2011;49:1135-61.
4. Rachner TD, Hadji P, Hofbauer LC. Novel therapies in benign and malignant bone diseases. Pharmacol Ther. 2012;134:338-44.
5. Arndt CA, Rose PS, Folpe AL, Laack NN. Commonmusculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 2012;87: 475-87.
6. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011;8:25-37.
7. Lauria A, Tutone M, IppolitoM, Pantano L, Almerico AM. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-mdm2 interaction and its inhibition by small molecules. Curr Med Chem. 2010;17:3142-54.
8. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a posttranslational modification at the edge of life and death. Nat Rev Mol Cell Biol. 2011;12:439-52.
9. Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-mdm2-p53 pathway. Oncogene. 2010;29:4253-60.
10. Knappskog S, Lonning PE. Effects of the mdm2 promoter snp285 and snp309 on sp1 transcription factor binding and cancer risk. Transcription. 2011;2:207-10.
11. Li Q, Lozano G. Molecular pathways: targeting mdm2 and mdm4 in cancer therapy. Clin Cancer Res. 2013;19:34-41.
12. ToffoliG, Biason P, Russo A, DeMattia E, Cecchin E, Hattinger CM, et al. Effect of tp53 arg72pro and mdm2 snp309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15:3550-6.
13. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both snp309 and mdm2 amplification in sarcomagenesis. Clin Cancer Res. 2011;17:416-26.
14. Mirabello L, Yu K, Berndt SI, Burdett L, Wang Z, Chowdhury S, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer. 2011;11:209.
15. Naumov VA, Generozov EV, Solovyov YN, Aliev MD, Kushlinsky NE. Association of fgfr3 and mdm2 gene nucleotide polymorphisms with bone tumors. Bull Exp Biol Med. 2012;153:869-73.
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology. JAMA. 2000;283:2008.
17. Mantel N, HaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
18. DerSimonian R, LairdN.Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
20. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26:1317-23.
21. Li Y, Zhao H, Sun L, Huang L, Yang Q, Kong B. Mdm2 snp309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 2011;24:57-64.
22. Cheng H, Ma B, Jiang R,Wang W, Guo H, Shen N, et al. Individual and combined effects of mdm2 snp309 and tp53 arg72pro on breast cancer risk: an updated meta-analysis.Mol Biol Rep. 2012;39:9265-74.
23. Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. Mdm2 snp309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma. 2012;53:2245-52.
24. Zhuo W, Zhang L, Zhu B, Ling J, Chen Z. Association of mdm2 snp309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One. 2012;7:e41546.
25. Ma Y, Bian J, Cao H. Mdm2 snp309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One. 2013;8:e56918.